NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=107875&from=4 CLASS PERIOD: August 1, 2022 to ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Outset Medical, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Tablo products during the specified class period [1][2]. Group 1: Allegations - The complaint alleges that Outset Medical made materially false and/or misleading statements regarding its Tablo products, which are primarily used in dialysis care [2]. - It is claimed that the Tablo products were marketed for continuous renal replacement therapy, an indication not approved by the FDA, leading to potential regulatory issues [2]. - The company is said to have lacked the necessary sales team and processes to effectively ramp up Tablo sales, which would adversely impact revenue growth [2]. Group 2: Class Action Details - The class period for the lawsuit is defined as August 1, 2022, to August 7, 2024, with a deadline for shareholders to register by October 28, 2024 [2][3]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case's status [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=106650&from=4 CLASS PERIOD: August 1, 2022 to ...

Core Viewpoint - A class action has been filed against Outset Medical, Inc. for allegedly misleading investors regarding its business prospects and the performance of its Tablo products [1][2]. Allegations - The complaint alleges that Outset Medical failed to disclose that its Tablo products were marketed for uses not approved by the FDA, which could lead to additional regulatory submissions [2]. - It is claimed that the company lacked the necessary sales team and processes to effectively ramp up sales of the Tablo products, which would adversely impact revenue growth [2]. - The positive statements made by the company regarding its business operations were allegedly materially misleading due to the undisclosed risks [2]. Financial Impact - On August 7, 2024, Outset Medical reported second quarter results that significantly missed consensus estimates and lowered its full-year revenue guidance by $39 million at the midpoint [3]. - Following the announcement, the company's share price dropped by $2.33, or 68.53%, closing at $1.07 per share on August 8, 2024, with unusually high trading volume [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by October 28, 2024 [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. About Robbins LLP - Robbins LLP is noted for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [5].

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=106373&from=3 CLASS PERIOD: August 1, 202 ...

SAN FRANCISCO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman encourages Outset Medical (NASDAQ: OM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may assist the investigation to contact its attorneys. On September 27, 2024, Outset Medical announced that it received notice from the Listing Qualifications staff of Nasdaq that "because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecu ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=104530&from=3 CLASS PERIOD: August 1, 20 ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Outset Medical, Inc. regarding a class action lawsuit alleging misleading statements and omissions related to the company's Tablo products used in dialysis care [1]. Group 1: Allegations - The complaint claims that during the class period from August 1, 2022, to August 7, 2024, Outset Medical made materially false and misleading statements about its Tablo products [1]. - It is alleged that the Tablo products were marketed for continuous renal replacement therapy, which is not FDA-approved, indicating potential regulatory issues [1]. - The company may need to submit an additional 510(k) application for the Tablo products, raising concerns about the continuation of sales pending FDA approval [1]. - There is a significant risk that Outset Medical would halt sales of the Tablo products until additional indications are approved by the FDA [1]. - The company reportedly lacks the necessary sales team and processes to effectively ramp up Tablo sales, which could adversely affect revenue growth [1]. - Due to these factors, the positive statements made by the defendants regarding the company's business and prospects were deemed materially misleading [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of Outset Medical during the specified class period are encouraged to register for the class action by October 28, 2024 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. - There is no cost or obligation for shareholders to participate in this class action [2].

Core Viewpoint - A class action securities lawsuit has been filed against Outset Medical, alleging securities fraud that affected investors between August 1, 2022, and August 7, 2024 [1] Group 1: Allegations of Fraud - The lawsuit claims that Outset Medical made false statements regarding its Tablo products, which are used in dialysis care, specifically marketing them for continuous renal replacement therapy without FDA approval [2] - It is alleged that Outset Medical was likely to submit an additional 510(k) application for the Tablo products due to the lack of approved indications [2] - The complaint indicates a substantial risk that Outset Medical would have to cease sales of the Tablo products pending FDA approval of additional indications [2] - The company reportedly lacked the necessary sales team and processes to effectively ramp up Tablo sales, which would adversely impact revenue growth [2] - Positive statements made by the defendants about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses in Outset Medical during the relevant time frame have until October 28, 2024, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4]

NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=103512&from=4 CLASS PERIOD: August 1, 2022 t ...